Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 4
1999 6
2000 10
2001 7
2002 13
2003 7
2004 16
2005 9
2006 10
2007 6
2008 3
2009 4
2010 6
2011 8
2012 8
2013 6
2014 6
2015 8
2016 3
2017 11
2018 8
2019 3
2020 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

148 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA. Kornblum N, et al. Among authors: manola j. J Clin Oncol. 2018 Jun 1;36(16):1556-1563. doi: 10.1200/JCO.2017.76.9331. Epub 2018 Apr 17. J Clin Oncol. 2018. PMID: 29664714 Free PMC article. Clinical Trial.
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D; Eastern Cooperative Oncology Group study EST 3886. Messing EM, et al. Among authors: manola j. Lancet Oncol. 2006 Jun;7(6):472-9. doi: 10.1016/S1470-2045(06)70700-8. Lancet Oncol. 2006. PMID: 16750497 Clinical Trial.
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Haas NB, et al. Among authors: manola j. Lancet. 2016 May 14;387(10032):2008-16. doi: 10.1016/S0140-6736(16)00559-6. Epub 2016 Mar 9. Lancet. 2016. PMID: 26969090 Free PMC article. Clinical Trial.
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward.
Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, Cella D, Gupta RT, Bhatt R, Van Allen E, Lara P, Choueiri TK, Kapoor A, Heng DYC, Shuch B, Jewett M, George D, Michaelson D, Carducci MA, McDermott D, Allaf M. Harshman LC, et al. Among authors: manola j. Kidney Cancer. 2017 Jul 26;1(1):31-40. doi: 10.3233/KCA-170010. Kidney Cancer. 2017. PMID: 30334002 Free PMC article. Review.
When bad things happen to good studies.
Manola JB, Gray RJ. Manola JB, et al. J Clin Oncol. 2011 Sep 10;29(26):3497-9. doi: 10.1200/JCO.2011.37.1393. Epub 2011 Aug 15. J Clin Oncol. 2011. PMID: 21844501 No abstract available.
Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.
Correa AF, Jegede OA, Haas NB, Flaherty KT, Pins MR, Adeniran A, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Correa AF, et al. Among authors: manola j. Eur Urol. 2021 Jul;80(1):20-31. doi: 10.1016/j.eururo.2021.02.025. Epub 2021 Mar 9. Eur Urol. 2021. PMID: 33707112 Free PMC article.
148 results